A growing body of evidence points out at chronic kidney disease (CKD) as a major risk factor for severe COVID-19, increasing also the respective mortality risk. Preventive measures, rapid monitoring organ function and interventions capable of preventing multiorgan failures are of great importance to reduce adverse outcomes in COVID-19 patients with CKD. While efforts are underway to carry out indirect protection interventions and large-scale vaccination to achieve herd immunity in the general population, direct protection of patients with CKD through rapid vaccination trials are necessary since uraemia and immunosuppressive agents could have a negative impact on vaccination responses of CDK patients. More epidemiological data are needed for in-depth understanding of the course and outcome of COVID-19 in CKD patients, supporting clinical decision-making.10.52547/ijkd.6797
No takes yet. Share an insight, caveat, or question.
Einollahi et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: